We are pleased to announce that the acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners has been completed. Read the Press Release

All Resources

Cell and Gene Therapy Insights: Can AAV continue to deliver the promise of gene therapy?

October 17, 2023

Charlotte Barker (Editor, BioInsights) speaks to Elie Hanania, PhD (Vice President of Process Development Viral Vector Technologies, Avid Bioservices) about the current status and future manufacturing of AAV-based gene therapies, including how to streamline large-scale manufacturing.

All Resources

Cell and Gene Therapy Insights: Can AAV continue to deliver the promise of gene therapy?

Sign up for Avid emails.

Follow Us:

Get the latest from Avid.

Follow Us:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content:

Please complete this form to access the content: